Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InspireMDSTU:II2 +0.75%47 Intrinsic Value: Projected FCF is €-1.83 as of Sep. 15, 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 413 Medical Devices & Instruments companies, InspireMD ranks worse than 242130.51% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-15), InspireMD's Intrinsic Value: Projected FCF is €-1.83. The stock price of InspireMD is €0.675. Therefore, InspireMD's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for InspireMD's Intrinsic Value: Projected FCF or its related term are showing as below:
STU:II2's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.46 * Ranked among companies with meaningful Price-to-Projected-FCF only.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
InspireMD's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.675
/
-1.9444455039931
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD Intrinsic Value: Projected FCF Related Terms
InspireMD Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for InspireMD's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:II2 vs SNWV, PAVM, ELUT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, InspireMD's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where InspireMD's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of €-1.83 mean?
InspireMD (STU:II2) has a Intrinsic Value: Projected FCF of €-1.83 as of Sep. 15, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #999999 out of 413 companies in the Medical Devices & Instruments industry.
Is InspireMD's Intrinsic Value: Projected FCF too high?
InspireMD's current Intrinsic Value: Projected FCF is €-1.83. Based on the distribution chart, InspireMD ranks #999999 out of 413 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Intrinsic Value: Projected FCF compare to SNWV and PAVM?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #999999 out of 413 companies for Intrinsic Value: Projected FCF. This places InspireMD in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.46, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Intrinsic Value: Projected FCF is €-1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.41, compared to a current price of €0.68 — trading 52.1% below its estimated fair value. The current Intrinsic Value: Projected FCF is €-1.83. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For InspireMD (STU:II2), the current Intrinsic Value: Projected FCF is €-1.83 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.68 is trading 52.1% below its estimated GF Value™ of €1.41.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
Intrinsic Value: Projected FCF: €-1.83
GF Value™: €1.41 vs. price of €0.68 (52.1% below fair value)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score
Get the complete analysis for STU:II2
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
